PMID- 25512461
OWN - NLM
STAT- MEDLINE
DCOM- 20160419
LR  - 20240325
IS  - 1527-7755 (Electronic)
IS  - 0732-183X (Print)
IS  - 0732-183X (Linking)
VI  - 33
IP  - 13
DP  - 2015 May 1
TI  - Randomized Phase II Trial of Gemcitabine Plus TH-302 Versus Gemcitabine in 
      Patients With Advanced Pancreatic Cancer.
PG  - 1475-81
LID - 10.1200/JCO.2014.55.7504 [doi]
AB  - PURPOSE: TH-302 is an investigational hypoxia-activated prodrug that releases the 
      DNA alkylator bromo-isophosphoramide mustard in hypoxic settings. This phase II 
      study (NCT01144455) evaluated gemcitabine plus TH-302 in patients with previously 
      untreated, locally advanced or metastatic pancreatic cancer. PATIENTS AND 
      METHODS: Patients were randomly assigned 1:1:1 to gemcitabine (1,000 mg/m(2)), 
      gemcitabine plus TH-302 240 mg/m(2) (G+T240), or gemcitabine plus TH-302 340 
      mg/m(2) (G+T340). Randomized crossover after progression on gemcitabine was 
      allowed. The primary end point was progression-free survival (PFS). Secondary end 
      points included overall survival (OS), tumor response, CA 19-9 response, and 
      safety. RESULTS: Two hundred fourteen patients (77% with metastatic disease) were 
      enrolled between June 2010 and July 2011. PFS was significantly longer with 
      gemcitabine plus TH-302 (pooled combination arms) compared with gemcitabine alone 
      (median PFS, 5.6 v 3.6 months, respectively; hazard ratio, 0.61; 95% CI, 0.43 to 
      0.87; P = .005; median PFS for metastatic disease, 5.1 v 3.4 months, 
      respectively). Median PFS times for G+T240 and G+T340 were 5.6 and 6.0 months, 
      respectively. Tumor response was 12%, 17%, and 26% in the gemcitabine, G+T240, 
      and G+T340 arms, respectively (G+T340 v gemcitabine, P = .04). CA 19-9 decrease 
      was greater with G+T340 versus gemcitabine (-5,398 v -549 U/mL, respectively; P = 
      .008). Median OS times for gemcitabine, G+T240, and G+T340 were 6.9, 8.7, and 9.2 
      months, respectively (P = not significant). The most common adverse events (AEs) 
      were fatigue, nausea, and peripheral edema (frequencies similar across arms). 
      Skin and mucosal toxicities (2% grade 3) and myelosuppression (55% grade 3 or 4) 
      were the most common TH-302-related AEs but were not associated with treatment 
      discontinuation. CONCLUSION: PFS, tumor response, and CA 19-9 response were 
      significantly improved with G+TH-302. G+T340 is being investigated further in the 
      phase III MAESTRO study (NCT01746979).
CI  - (c) 2014 by American Society of Clinical Oncology.
FAU - Borad, Mitesh J
AU  - Borad MJ
AD  - Mitesh J. Borad, Mayo Clinic, Scottsdale; Tomislav Dragovich, Arizona Cancer 
      Center, Tucson, AZ; Shantan G. Reddy, Louisiana State University Health Sciences 
      Center Shreveport, Shreveport, LA; Nathan Bahary, University of Pittsburgh 
      Medical Center, Pittsburgh, PA; Hope E. Uronis, Duke University Medical Center, 
      Durham, NC; Darren Sigal, Scripps Clinic, La Jolla; Peter J. Rosen, Disney Family 
      Cancer Center, Burbank; Clarence Eng and Stew Kroll, Threshold Pharmaceuticals, 
      South San Francisco, CA; Allen L. Cohn, Rocky Mountain Cancer Center, Denver, CO; 
      William R. Schelman, University of Wisconsin Carbone Cancer Center, Madison, WI; 
      Joe Stephenson Jr, Institute for Translational Oncology Research, Greenville, SC; 
      E. Gabriela Chiorean, Indiana University Simon Cancer Center, Indianapolis, IN; 
      Brian Ulrich, Texas Oncology, Wichita Falls, TX; Salvatore A. Del Prete, 
      Hematology Oncology PC, Stamford, CT; Mark Rarick, Kaiser Permanente Northwest 
      Region Oncology Hematology, Portland, OR; and David P. Ryan, Massachusetts 
      General Hospital Cancer Center, Boston, MA. Borad.mitesh@mayo.edu.
FAU - Reddy, Shantan G
AU  - Reddy SG
AD  - Mitesh J. Borad, Mayo Clinic, Scottsdale; Tomislav Dragovich, Arizona Cancer 
      Center, Tucson, AZ; Shantan G. Reddy, Louisiana State University Health Sciences 
      Center Shreveport, Shreveport, LA; Nathan Bahary, University of Pittsburgh 
      Medical Center, Pittsburgh, PA; Hope E. Uronis, Duke University Medical Center, 
      Durham, NC; Darren Sigal, Scripps Clinic, La Jolla; Peter J. Rosen, Disney Family 
      Cancer Center, Burbank; Clarence Eng and Stew Kroll, Threshold Pharmaceuticals, 
      South San Francisco, CA; Allen L. Cohn, Rocky Mountain Cancer Center, Denver, CO; 
      William R. Schelman, University of Wisconsin Carbone Cancer Center, Madison, WI; 
      Joe Stephenson Jr, Institute for Translational Oncology Research, Greenville, SC; 
      E. Gabriela Chiorean, Indiana University Simon Cancer Center, Indianapolis, IN; 
      Brian Ulrich, Texas Oncology, Wichita Falls, TX; Salvatore A. Del Prete, 
      Hematology Oncology PC, Stamford, CT; Mark Rarick, Kaiser Permanente Northwest 
      Region Oncology Hematology, Portland, OR; and David P. Ryan, Massachusetts 
      General Hospital Cancer Center, Boston, MA.
FAU - Bahary, Nathan
AU  - Bahary N
AD  - Mitesh J. Borad, Mayo Clinic, Scottsdale; Tomislav Dragovich, Arizona Cancer 
      Center, Tucson, AZ; Shantan G. Reddy, Louisiana State University Health Sciences 
      Center Shreveport, Shreveport, LA; Nathan Bahary, University of Pittsburgh 
      Medical Center, Pittsburgh, PA; Hope E. Uronis, Duke University Medical Center, 
      Durham, NC; Darren Sigal, Scripps Clinic, La Jolla; Peter J. Rosen, Disney Family 
      Cancer Center, Burbank; Clarence Eng and Stew Kroll, Threshold Pharmaceuticals, 
      South San Francisco, CA; Allen L. Cohn, Rocky Mountain Cancer Center, Denver, CO; 
      William R. Schelman, University of Wisconsin Carbone Cancer Center, Madison, WI; 
      Joe Stephenson Jr, Institute for Translational Oncology Research, Greenville, SC; 
      E. Gabriela Chiorean, Indiana University Simon Cancer Center, Indianapolis, IN; 
      Brian Ulrich, Texas Oncology, Wichita Falls, TX; Salvatore A. Del Prete, 
      Hematology Oncology PC, Stamford, CT; Mark Rarick, Kaiser Permanente Northwest 
      Region Oncology Hematology, Portland, OR; and David P. Ryan, Massachusetts 
      General Hospital Cancer Center, Boston, MA.
FAU - Uronis, Hope E
AU  - Uronis HE
AD  - Mitesh J. Borad, Mayo Clinic, Scottsdale; Tomislav Dragovich, Arizona Cancer 
      Center, Tucson, AZ; Shantan G. Reddy, Louisiana State University Health Sciences 
      Center Shreveport, Shreveport, LA; Nathan Bahary, University of Pittsburgh 
      Medical Center, Pittsburgh, PA; Hope E. Uronis, Duke University Medical Center, 
      Durham, NC; Darren Sigal, Scripps Clinic, La Jolla; Peter J. Rosen, Disney Family 
      Cancer Center, Burbank; Clarence Eng and Stew Kroll, Threshold Pharmaceuticals, 
      South San Francisco, CA; Allen L. Cohn, Rocky Mountain Cancer Center, Denver, CO; 
      William R. Schelman, University of Wisconsin Carbone Cancer Center, Madison, WI; 
      Joe Stephenson Jr, Institute for Translational Oncology Research, Greenville, SC; 
      E. Gabriela Chiorean, Indiana University Simon Cancer Center, Indianapolis, IN; 
      Brian Ulrich, Texas Oncology, Wichita Falls, TX; Salvatore A. Del Prete, 
      Hematology Oncology PC, Stamford, CT; Mark Rarick, Kaiser Permanente Northwest 
      Region Oncology Hematology, Portland, OR; and David P. Ryan, Massachusetts 
      General Hospital Cancer Center, Boston, MA.
FAU - Sigal, Darren
AU  - Sigal D
AD  - Mitesh J. Borad, Mayo Clinic, Scottsdale; Tomislav Dragovich, Arizona Cancer 
      Center, Tucson, AZ; Shantan G. Reddy, Louisiana State University Health Sciences 
      Center Shreveport, Shreveport, LA; Nathan Bahary, University of Pittsburgh 
      Medical Center, Pittsburgh, PA; Hope E. Uronis, Duke University Medical Center, 
      Durham, NC; Darren Sigal, Scripps Clinic, La Jolla; Peter J. Rosen, Disney Family 
      Cancer Center, Burbank; Clarence Eng and Stew Kroll, Threshold Pharmaceuticals, 
      South San Francisco, CA; Allen L. Cohn, Rocky Mountain Cancer Center, Denver, CO; 
      William R. Schelman, University of Wisconsin Carbone Cancer Center, Madison, WI; 
      Joe Stephenson Jr, Institute for Translational Oncology Research, Greenville, SC; 
      E. Gabriela Chiorean, Indiana University Simon Cancer Center, Indianapolis, IN; 
      Brian Ulrich, Texas Oncology, Wichita Falls, TX; Salvatore A. Del Prete, 
      Hematology Oncology PC, Stamford, CT; Mark Rarick, Kaiser Permanente Northwest 
      Region Oncology Hematology, Portland, OR; and David P. Ryan, Massachusetts 
      General Hospital Cancer Center, Boston, MA.
FAU - Cohn, Allen L
AU  - Cohn AL
AD  - Mitesh J. Borad, Mayo Clinic, Scottsdale; Tomislav Dragovich, Arizona Cancer 
      Center, Tucson, AZ; Shantan G. Reddy, Louisiana State University Health Sciences 
      Center Shreveport, Shreveport, LA; Nathan Bahary, University of Pittsburgh 
      Medical Center, Pittsburgh, PA; Hope E. Uronis, Duke University Medical Center, 
      Durham, NC; Darren Sigal, Scripps Clinic, La Jolla; Peter J. Rosen, Disney Family 
      Cancer Center, Burbank; Clarence Eng and Stew Kroll, Threshold Pharmaceuticals, 
      South San Francisco, CA; Allen L. Cohn, Rocky Mountain Cancer Center, Denver, CO; 
      William R. Schelman, University of Wisconsin Carbone Cancer Center, Madison, WI; 
      Joe Stephenson Jr, Institute for Translational Oncology Research, Greenville, SC; 
      E. Gabriela Chiorean, Indiana University Simon Cancer Center, Indianapolis, IN; 
      Brian Ulrich, Texas Oncology, Wichita Falls, TX; Salvatore A. Del Prete, 
      Hematology Oncology PC, Stamford, CT; Mark Rarick, Kaiser Permanente Northwest 
      Region Oncology Hematology, Portland, OR; and David P. Ryan, Massachusetts 
      General Hospital Cancer Center, Boston, MA.
FAU - Schelman, William R
AU  - Schelman WR
AD  - Mitesh J. Borad, Mayo Clinic, Scottsdale; Tomislav Dragovich, Arizona Cancer 
      Center, Tucson, AZ; Shantan G. Reddy, Louisiana State University Health Sciences 
      Center Shreveport, Shreveport, LA; Nathan Bahary, University of Pittsburgh 
      Medical Center, Pittsburgh, PA; Hope E. Uronis, Duke University Medical Center, 
      Durham, NC; Darren Sigal, Scripps Clinic, La Jolla; Peter J. Rosen, Disney Family 
      Cancer Center, Burbank; Clarence Eng and Stew Kroll, Threshold Pharmaceuticals, 
      South San Francisco, CA; Allen L. Cohn, Rocky Mountain Cancer Center, Denver, CO; 
      William R. Schelman, University of Wisconsin Carbone Cancer Center, Madison, WI; 
      Joe Stephenson Jr, Institute for Translational Oncology Research, Greenville, SC; 
      E. Gabriela Chiorean, Indiana University Simon Cancer Center, Indianapolis, IN; 
      Brian Ulrich, Texas Oncology, Wichita Falls, TX; Salvatore A. Del Prete, 
      Hematology Oncology PC, Stamford, CT; Mark Rarick, Kaiser Permanente Northwest 
      Region Oncology Hematology, Portland, OR; and David P. Ryan, Massachusetts 
      General Hospital Cancer Center, Boston, MA.
FAU - Stephenson, Joe Jr
AU  - Stephenson J Jr
AD  - Mitesh J. Borad, Mayo Clinic, Scottsdale; Tomislav Dragovich, Arizona Cancer 
      Center, Tucson, AZ; Shantan G. Reddy, Louisiana State University Health Sciences 
      Center Shreveport, Shreveport, LA; Nathan Bahary, University of Pittsburgh 
      Medical Center, Pittsburgh, PA; Hope E. Uronis, Duke University Medical Center, 
      Durham, NC; Darren Sigal, Scripps Clinic, La Jolla; Peter J. Rosen, Disney Family 
      Cancer Center, Burbank; Clarence Eng and Stew Kroll, Threshold Pharmaceuticals, 
      South San Francisco, CA; Allen L. Cohn, Rocky Mountain Cancer Center, Denver, CO; 
      William R. Schelman, University of Wisconsin Carbone Cancer Center, Madison, WI; 
      Joe Stephenson Jr, Institute for Translational Oncology Research, Greenville, SC; 
      E. Gabriela Chiorean, Indiana University Simon Cancer Center, Indianapolis, IN; 
      Brian Ulrich, Texas Oncology, Wichita Falls, TX; Salvatore A. Del Prete, 
      Hematology Oncology PC, Stamford, CT; Mark Rarick, Kaiser Permanente Northwest 
      Region Oncology Hematology, Portland, OR; and David P. Ryan, Massachusetts 
      General Hospital Cancer Center, Boston, MA.
FAU - Chiorean, E Gabriela
AU  - Chiorean EG
AD  - Mitesh J. Borad, Mayo Clinic, Scottsdale; Tomislav Dragovich, Arizona Cancer 
      Center, Tucson, AZ; Shantan G. Reddy, Louisiana State University Health Sciences 
      Center Shreveport, Shreveport, LA; Nathan Bahary, University of Pittsburgh 
      Medical Center, Pittsburgh, PA; Hope E. Uronis, Duke University Medical Center, 
      Durham, NC; Darren Sigal, Scripps Clinic, La Jolla; Peter J. Rosen, Disney Family 
      Cancer Center, Burbank; Clarence Eng and Stew Kroll, Threshold Pharmaceuticals, 
      South San Francisco, CA; Allen L. Cohn, Rocky Mountain Cancer Center, Denver, CO; 
      William R. Schelman, University of Wisconsin Carbone Cancer Center, Madison, WI; 
      Joe Stephenson Jr, Institute for Translational Oncology Research, Greenville, SC; 
      E. Gabriela Chiorean, Indiana University Simon Cancer Center, Indianapolis, IN; 
      Brian Ulrich, Texas Oncology, Wichita Falls, TX; Salvatore A. Del Prete, 
      Hematology Oncology PC, Stamford, CT; Mark Rarick, Kaiser Permanente Northwest 
      Region Oncology Hematology, Portland, OR; and David P. Ryan, Massachusetts 
      General Hospital Cancer Center, Boston, MA.
FAU - Rosen, Peter J
AU  - Rosen PJ
AD  - Mitesh J. Borad, Mayo Clinic, Scottsdale; Tomislav Dragovich, Arizona Cancer 
      Center, Tucson, AZ; Shantan G. Reddy, Louisiana State University Health Sciences 
      Center Shreveport, Shreveport, LA; Nathan Bahary, University of Pittsburgh 
      Medical Center, Pittsburgh, PA; Hope E. Uronis, Duke University Medical Center, 
      Durham, NC; Darren Sigal, Scripps Clinic, La Jolla; Peter J. Rosen, Disney Family 
      Cancer Center, Burbank; Clarence Eng and Stew Kroll, Threshold Pharmaceuticals, 
      South San Francisco, CA; Allen L. Cohn, Rocky Mountain Cancer Center, Denver, CO; 
      William R. Schelman, University of Wisconsin Carbone Cancer Center, Madison, WI; 
      Joe Stephenson Jr, Institute for Translational Oncology Research, Greenville, SC; 
      E. Gabriela Chiorean, Indiana University Simon Cancer Center, Indianapolis, IN; 
      Brian Ulrich, Texas Oncology, Wichita Falls, TX; Salvatore A. Del Prete, 
      Hematology Oncology PC, Stamford, CT; Mark Rarick, Kaiser Permanente Northwest 
      Region Oncology Hematology, Portland, OR; and David P. Ryan, Massachusetts 
      General Hospital Cancer Center, Boston, MA.
FAU - Ulrich, Brian
AU  - Ulrich B
AD  - Mitesh J. Borad, Mayo Clinic, Scottsdale; Tomislav Dragovich, Arizona Cancer 
      Center, Tucson, AZ; Shantan G. Reddy, Louisiana State University Health Sciences 
      Center Shreveport, Shreveport, LA; Nathan Bahary, University of Pittsburgh 
      Medical Center, Pittsburgh, PA; Hope E. Uronis, Duke University Medical Center, 
      Durham, NC; Darren Sigal, Scripps Clinic, La Jolla; Peter J. Rosen, Disney Family 
      Cancer Center, Burbank; Clarence Eng and Stew Kroll, Threshold Pharmaceuticals, 
      South San Francisco, CA; Allen L. Cohn, Rocky Mountain Cancer Center, Denver, CO; 
      William R. Schelman, University of Wisconsin Carbone Cancer Center, Madison, WI; 
      Joe Stephenson Jr, Institute for Translational Oncology Research, Greenville, SC; 
      E. Gabriela Chiorean, Indiana University Simon Cancer Center, Indianapolis, IN; 
      Brian Ulrich, Texas Oncology, Wichita Falls, TX; Salvatore A. Del Prete, 
      Hematology Oncology PC, Stamford, CT; Mark Rarick, Kaiser Permanente Northwest 
      Region Oncology Hematology, Portland, OR; and David P. Ryan, Massachusetts 
      General Hospital Cancer Center, Boston, MA.
FAU - Dragovich, Tomislav
AU  - Dragovich T
AD  - Mitesh J. Borad, Mayo Clinic, Scottsdale; Tomislav Dragovich, Arizona Cancer 
      Center, Tucson, AZ; Shantan G. Reddy, Louisiana State University Health Sciences 
      Center Shreveport, Shreveport, LA; Nathan Bahary, University of Pittsburgh 
      Medical Center, Pittsburgh, PA; Hope E. Uronis, Duke University Medical Center, 
      Durham, NC; Darren Sigal, Scripps Clinic, La Jolla; Peter J. Rosen, Disney Family 
      Cancer Center, Burbank; Clarence Eng and Stew Kroll, Threshold Pharmaceuticals, 
      South San Francisco, CA; Allen L. Cohn, Rocky Mountain Cancer Center, Denver, CO; 
      William R. Schelman, University of Wisconsin Carbone Cancer Center, Madison, WI; 
      Joe Stephenson Jr, Institute for Translational Oncology Research, Greenville, SC; 
      E. Gabriela Chiorean, Indiana University Simon Cancer Center, Indianapolis, IN; 
      Brian Ulrich, Texas Oncology, Wichita Falls, TX; Salvatore A. Del Prete, 
      Hematology Oncology PC, Stamford, CT; Mark Rarick, Kaiser Permanente Northwest 
      Region Oncology Hematology, Portland, OR; and David P. Ryan, Massachusetts 
      General Hospital Cancer Center, Boston, MA.
FAU - Del Prete, Salvatore A
AU  - Del Prete SA
AD  - Mitesh J. Borad, Mayo Clinic, Scottsdale; Tomislav Dragovich, Arizona Cancer 
      Center, Tucson, AZ; Shantan G. Reddy, Louisiana State University Health Sciences 
      Center Shreveport, Shreveport, LA; Nathan Bahary, University of Pittsburgh 
      Medical Center, Pittsburgh, PA; Hope E. Uronis, Duke University Medical Center, 
      Durham, NC; Darren Sigal, Scripps Clinic, La Jolla; Peter J. Rosen, Disney Family 
      Cancer Center, Burbank; Clarence Eng and Stew Kroll, Threshold Pharmaceuticals, 
      South San Francisco, CA; Allen L. Cohn, Rocky Mountain Cancer Center, Denver, CO; 
      William R. Schelman, University of Wisconsin Carbone Cancer Center, Madison, WI; 
      Joe Stephenson Jr, Institute for Translational Oncology Research, Greenville, SC; 
      E. Gabriela Chiorean, Indiana University Simon Cancer Center, Indianapolis, IN; 
      Brian Ulrich, Texas Oncology, Wichita Falls, TX; Salvatore A. Del Prete, 
      Hematology Oncology PC, Stamford, CT; Mark Rarick, Kaiser Permanente Northwest 
      Region Oncology Hematology, Portland, OR; and David P. Ryan, Massachusetts 
      General Hospital Cancer Center, Boston, MA.
FAU - Rarick, Mark
AU  - Rarick M
AD  - Mitesh J. Borad, Mayo Clinic, Scottsdale; Tomislav Dragovich, Arizona Cancer 
      Center, Tucson, AZ; Shantan G. Reddy, Louisiana State University Health Sciences 
      Center Shreveport, Shreveport, LA; Nathan Bahary, University of Pittsburgh 
      Medical Center, Pittsburgh, PA; Hope E. Uronis, Duke University Medical Center, 
      Durham, NC; Darren Sigal, Scripps Clinic, La Jolla; Peter J. Rosen, Disney Family 
      Cancer Center, Burbank; Clarence Eng and Stew Kroll, Threshold Pharmaceuticals, 
      South San Francisco, CA; Allen L. Cohn, Rocky Mountain Cancer Center, Denver, CO; 
      William R. Schelman, University of Wisconsin Carbone Cancer Center, Madison, WI; 
      Joe Stephenson Jr, Institute for Translational Oncology Research, Greenville, SC; 
      E. Gabriela Chiorean, Indiana University Simon Cancer Center, Indianapolis, IN; 
      Brian Ulrich, Texas Oncology, Wichita Falls, TX; Salvatore A. Del Prete, 
      Hematology Oncology PC, Stamford, CT; Mark Rarick, Kaiser Permanente Northwest 
      Region Oncology Hematology, Portland, OR; and David P. Ryan, Massachusetts 
      General Hospital Cancer Center, Boston, MA.
FAU - Eng, Clarence
AU  - Eng C
AD  - Mitesh J. Borad, Mayo Clinic, Scottsdale; Tomislav Dragovich, Arizona Cancer 
      Center, Tucson, AZ; Shantan G. Reddy, Louisiana State University Health Sciences 
      Center Shreveport, Shreveport, LA; Nathan Bahary, University of Pittsburgh 
      Medical Center, Pittsburgh, PA; Hope E. Uronis, Duke University Medical Center, 
      Durham, NC; Darren Sigal, Scripps Clinic, La Jolla; Peter J. Rosen, Disney Family 
      Cancer Center, Burbank; Clarence Eng and Stew Kroll, Threshold Pharmaceuticals, 
      South San Francisco, CA; Allen L. Cohn, Rocky Mountain Cancer Center, Denver, CO; 
      William R. Schelman, University of Wisconsin Carbone Cancer Center, Madison, WI; 
      Joe Stephenson Jr, Institute for Translational Oncology Research, Greenville, SC; 
      E. Gabriela Chiorean, Indiana University Simon Cancer Center, Indianapolis, IN; 
      Brian Ulrich, Texas Oncology, Wichita Falls, TX; Salvatore A. Del Prete, 
      Hematology Oncology PC, Stamford, CT; Mark Rarick, Kaiser Permanente Northwest 
      Region Oncology Hematology, Portland, OR; and David P. Ryan, Massachusetts 
      General Hospital Cancer Center, Boston, MA.
FAU - Kroll, Stew
AU  - Kroll S
AD  - Mitesh J. Borad, Mayo Clinic, Scottsdale; Tomislav Dragovich, Arizona Cancer 
      Center, Tucson, AZ; Shantan G. Reddy, Louisiana State University Health Sciences 
      Center Shreveport, Shreveport, LA; Nathan Bahary, University of Pittsburgh 
      Medical Center, Pittsburgh, PA; Hope E. Uronis, Duke University Medical Center, 
      Durham, NC; Darren Sigal, Scripps Clinic, La Jolla; Peter J. Rosen, Disney Family 
      Cancer Center, Burbank; Clarence Eng and Stew Kroll, Threshold Pharmaceuticals, 
      South San Francisco, CA; Allen L. Cohn, Rocky Mountain Cancer Center, Denver, CO; 
      William R. Schelman, University of Wisconsin Carbone Cancer Center, Madison, WI; 
      Joe Stephenson Jr, Institute for Translational Oncology Research, Greenville, SC; 
      E. Gabriela Chiorean, Indiana University Simon Cancer Center, Indianapolis, IN; 
      Brian Ulrich, Texas Oncology, Wichita Falls, TX; Salvatore A. Del Prete, 
      Hematology Oncology PC, Stamford, CT; Mark Rarick, Kaiser Permanente Northwest 
      Region Oncology Hematology, Portland, OR; and David P. Ryan, Massachusetts 
      General Hospital Cancer Center, Boston, MA.
FAU - Ryan, David P
AU  - Ryan DP
AD  - Mitesh J. Borad, Mayo Clinic, Scottsdale; Tomislav Dragovich, Arizona Cancer 
      Center, Tucson, AZ; Shantan G. Reddy, Louisiana State University Health Sciences 
      Center Shreveport, Shreveport, LA; Nathan Bahary, University of Pittsburgh 
      Medical Center, Pittsburgh, PA; Hope E. Uronis, Duke University Medical Center, 
      Durham, NC; Darren Sigal, Scripps Clinic, La Jolla; Peter J. Rosen, Disney Family 
      Cancer Center, Burbank; Clarence Eng and Stew Kroll, Threshold Pharmaceuticals, 
      South San Francisco, CA; Allen L. Cohn, Rocky Mountain Cancer Center, Denver, CO; 
      William R. Schelman, University of Wisconsin Carbone Cancer Center, Madison, WI; 
      Joe Stephenson Jr, Institute for Translational Oncology Research, Greenville, SC; 
      E. Gabriela Chiorean, Indiana University Simon Cancer Center, Indianapolis, IN; 
      Brian Ulrich, Texas Oncology, Wichita Falls, TX; Salvatore A. Del Prete, 
      Hematology Oncology PC, Stamford, CT; Mark Rarick, Kaiser Permanente Northwest 
      Region Oncology Hematology, Portland, OR; and David P. Ryan, Massachusetts 
      General Hospital Cancer Center, Boston, MA.
LA  - eng
SI  - ClinicalTrials.gov/NCT01144455
SI  - ClinicalTrials.gov/NCT01746979
SI  - ClinicalTrials.gov/NCT01144455
GR  - UL1 TR000427/TR/NCATS NIH HHS/United States
PT  - Clinical Trial, Phase II
PT  - Comparative Study
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20141215
PL  - United States
TA  - J Clin Oncol
JT  - Journal of clinical oncology : official journal of the American Society of 
      Clinical Oncology
JID - 8309333
RN  - 0 (Nitroimidazoles)
RN  - 0 (Phosphoramide Mustards)
RN  - 0 (TH 302)
RN  - 0W860991D6 (Deoxycytidine)
RN  - 0 (Gemcitabine)
SB  - IM
CIN - J Clin Oncol. 2015 May 1;33(13):1505-8. PMID: 25800764
CIN - Strahlenther Onkol. 2015 Oct;191(10):819-20. PMID: 26385861
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Antineoplastic Combined Chemotherapy Protocols/adverse effects/*therapeutic use
MH  - Deoxycytidine/administration & dosage/analogs & derivatives
MH  - Disease Progression
MH  - Disease-Free Survival
MH  - Humans
MH  - Kaplan-Meier Estimate
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Staging
MH  - Nitroimidazoles/administration & dosage
MH  - Pancreatic Neoplasms/*drug therapy/mortality/pathology
MH  - Phosphoramide Mustards/administration & dosage
MH  - Proportional Hazards Models
MH  - Time Factors
MH  - Treatment Outcome
MH  - United States
MH  - Gemcitabine
PMC - PMC4881365
COIS- Authors' disclosures of potential conflicts of interest and author contributions 
      are found at the end of this article.
EDAT- 2014/12/17 06:00
MHDA- 2016/04/20 06:00
PMCR- 2014/12/15
CRDT- 2014/12/17 06:00
PHST- 2014/12/17 06:00 [entrez]
PHST- 2014/12/17 06:00 [pubmed]
PHST- 2016/04/20 06:00 [medline]
PHST- 2014/12/15 00:00 [pmc-release]
AID - JCO.2014.55.7504 [pii]
AID - 57504 [pii]
AID - 10.1200/JCO.2014.55.7504 [doi]
PST - ppublish
SO  - J Clin Oncol. 2015 May 1;33(13):1475-81. doi: 10.1200/JCO.2014.55.7504. Epub 2014 
      Dec 15.